

## AMENDMENT TO THE CLAIMS

Claims 1-19 (Cancelled)

20. (Currently Amended) An isolated nucleic acid of at least 12 contiguous nucleotides in length selected from the group consisting of (a) a nucleic acid consisting of SEQ ID NO:1; (b) a nucleic acid consisting of SEQ ID NO:4; (c) a nucleic acid complementary to SEQ ID NO:1, and (d) a nucleic acid complementary to SEQ ID NO:4 wherein said isolated nucleic acid of (a), (b), (c), or (d) is capable of specifically binding to the complement of the polynucleotide of SEQ ID NO:1; the complement of the polynucleotide of SEQ ID NO:4; SEQ ID NO:1; or SEQ ID NO:4, respectively, with the proviso that said isolated nucleic acid is not ATGAGAATTCGA (SEQ ID NO:12) or the complement thereof.

21. (Previously Amended) The nucleic acid of claim 20 which is 12 to about 75 contiguous nucleotides in length.

22. (Previously Amended) The nucleic acid of claim 20 which is 12 to 14 nucleotides in length.

23. (Currently Amended) An isolated nucleic acid of at least The nucleic acid of claim 20 which is 14 to 18 nucleotides in length selected from the group consisting of (a) a nucleic acid consisting of SEQ ID NO:1; (b) a nucleic acid consisting of SEQ ID NO:4; (c) a nucleic acid complementary to SEQ ID NO:1, and (d) a nucleic acid complementary to SEQ ID NO:4 wherein said isolated nucleic acid of (a), (b), (c), or (d) is capable of specifically binding to the complement of the polynucleotide of SEQ ID NO:1; the complement of the polynucleotide of SEQ ID NO:4; SEQ ID NO:1; or SEQ ID NO:4, respectively.

24. (Currently Amended) The nucleic acid of claim 23 which is 18 to 20 nucleotides in length.

25. (Currently Amended) The nucleic acid of claim 23 which is 20 to about 75 nucleotides in length.

26. (Currently Amended) The nucleic acid of claim 20 or 23 labeled with a radioactive, fluorescent, enzymatic, or chromogenic marker.

27. (Currently Amended) The nucleic acid of claim 20 or 23 wherein the nucleic acid is DNA.

28. (Previously Amended) The nucleic acid of claim 27 selected from the group consisting of (a) a nucleic acid consisting of SEQ ID NO:9; (b) a nucleic acid consisting of

SEQ ID NO:10; (c) a nucleic acid consisting of SEQ ID NO:11; (d) a nucleic acid complementary to SEQ ID NO:9; (e) a nucleic acid complementary to SEQ ID NO:10; and (f) a nucleic acid complementary to SEQ ID NO:11.

29. (Previously Presented) The nucleic acid of claim 27 selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11.

30. (Previously Amended) A composition comprising the nucleic acid of claim 20 and a diluent or carrier.

Claims 31-33 (Cancelled)

34. (Previously Amended) The nucleic acid of claim 20 wherein the nucleic acid is DNA, or RNA.

35. (Previously Presented) The nucleic acid of claim 20 where the nucleic is RNA.

Claims 36-40 (Cancelled)

41. (Currently Presented) An oligonucleotide of at least 14 nucleotides in length capable of specifically hybridizing, under conditions of moderate-high stringency, to a nucleic acid which encodes a polypeptide comprising SEQ ID NO:3 or SEQ ID NO:6.

42. (Previously Presented) The oligonucleotide of claim 41 which is DNA or RNA.

43. (Previously Presented) The oligonucleotide of claim 41 which is DNA.

44. (Previously Presented) The oligonucleotide of claim 41 which is RNA.

45. (Previously Presented) A composition comprising the oligonucleotide of claim 41 and a pharmaceutically acceptable diluent or carrier.